X
[{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Omega Funds","pharmaFlowCategory":"D","amount":"$88.0 million","upfrontCash":"Undisclosed","newsHeadline":"Spruce Biosciences Raises $88 Million in Series B Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spruce Biosciences Announces Launch of CAHstudy.com to Initiate Screening of Patients for CAH Clinical Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spruce Bio Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at European Congress of Endocrinology","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$15.0 million","newsHeadline":"Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"5am Ventures","pharmaFlowCategory":"D","amount":"$53.6 million","upfrontCash":"Undisclosed","newsHeadline":"Spruce Biosciences Announces $53.6 Million Private Placement Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spruce Biosciences Announces Acceptance of Abstract for Presentation at ENDO 2022 Annual Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spruce Biosciences Completes Target Enrollment of CAHmelia-203 Study in Adult Classic Congenital Adrenal Hyperplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals for Tildacerfont
Filters
Companies By Therapeutic Area
Details:
SPR001 (tildacerfont) is a potent and highly selective, non-steroidal, once-daily oral antagonist of the CRF1 receptor, which is being developed for the treatment of adult classic congenital adrenal hyperplasia (CAH)
Lead Product(s):
Tildacerfont
Therapeutic Area: Genetic Disease
Product Name: SPR001
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 13, 2024
Details:
SPR001 (tildacerfont) is a potent and highly selective, non-steroidal, once-daily oral antagonist of the CRF1 receptor. It is being evaluated in phase 2 clinical trials for the treatment of congenial adrenal hyperplasia.
Lead Product(s):
Tildacerfont
Therapeutic Area: Genetic Disease
Product Name: SPR001
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 22, 2024
Details:
SPR001 (tildacerfont) is a potent and highly selective, non-steroidal, oral antagonist of the CRF1 receptor, which is investigated for the treatment of adult Classic Congenital Adrenal Hyperplasia.
Lead Product(s):
Tildacerfont
Therapeutic Area: Genetic Disease
Product Name: SPR001
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 18, 2023
Details:
The Company expects to use the net proceeds from the Offering, for the advancement of the Company’s clinical development programs, including SPR001 (tildacerfont) and for working capital and other general corporate purposes.
Lead Product(s):
Tildacerfont
Therapeutic Area: Genetic Disease
Product Name: SPR001
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
5am Ventures
Deal Size: $53.6 million
Upfront Cash: Undisclosed
Deal Type: Private Placement
February 09, 2023
Details:
SPR001 (tildacerfont) is a potent and highly selective, non-steroidal, oral antagonist of the corticotropin-releasing factor (CRF) 1 receptor. The CRF1 receptor is abundantly expressed in the pituitary gland where it is the primary regulator of the HPA axis.
Lead Product(s):
Tildacerfont
Therapeutic Area: Genetic Disease
Product Name: SPR001
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Kaken Pharmaceuticals
Deal Size: Undisclosed
Upfront Cash: $15.0 million
Deal Type: Partnership
January 05, 2023
Details:
Spruce is developing its wholly-owned product candidate, SPR001 (tildacerfont), as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH).
Lead Product(s):
Tildacerfont
Therapeutic Area: Genetic Disease
Product Name: SPR001
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 31, 2022
Details:
Tildacerfont has been evaluated in 171 patients across seven clinical trials in which it has been generally well tolerated. No drug-related serious adverse events have been reported related to tildacerfont treatment.
Lead Product(s):
Tildacerfont
Therapeutic Area: Genetic Disease
Product Name: SPR001
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 24, 2021
Details:
The CAHmelia clinical program is designed to evaluate the efficacy of tildacerfont, an investigational, oral, once-a-day corticotropin-releasing factor type-1 receptor antagonist, in two placebo-controlled, late stage clinical studies in adults with Classic CAH.
Lead Product(s):
Tildacerfont
Therapeutic Area: Genetic Disease
Product Name: Undisclosed
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 12, 2020
Details:
The proceeds will be used to further fund the clinical development of the company’s lead product, tildacerfont, in classic congenital adrenal hyperplasia (CAH) and other conditions.
Lead Product(s):
Tildacerfont
Therapeutic Area: Genetic Disease
Product Name: Undisclosed
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Omega Funds
Deal Size: $88.0 million
Upfront Cash: Undisclosed
Deal Type: Series B Financing
February 19, 2020